Clinical Trials Logo

Filter by:
NCT ID: NCT03703466 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.

NCT ID: NCT03703297 Recruiting - Clinical trials for Small Cell Lung Cancer

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Start date: September 27, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III LD-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT ID: NCT03703128 Recruiting - Suicide Clinical Trials

Suicide in People Aged 45-60: A Case-control Psychological Autopsy Study

Start date: September 28, 2018
Study type: Observational

The purpose of this study is to learn about the possible causes of the negative trend in suicide rates in both males and females aged 45-60 in Flanders, Belgium. This will be carried out using a psychological autopsy study.

NCT ID: NCT03700268 Recruiting - Clinical trials for Deafness; Perception

Programming Cochlear Implant With Artificial Intelligence

Start date: September 4, 2017
Phase: N/A
Study type: Interventional

This thesis project proposes to investigate the "state of the art" of the programming of the cochlear implant. In the center of audiophonologie Brussels, the classic 'manual programming' has been in use over 20 years and also the new way 'Artificial Intelligence programming'. The investigators want to compare, objectify, and control this new mode of programming. The study is planned over 4 years, in order to test, randomized, 15 subjects with manual programming and 15 other subjects with Artificial Intelligence programming. To test the performance of Cochlear Implant patients, audiological, language auditory perception and questionnaire tests will be presented. This research aims to determine the contribution and results of Artificial Intelligence programming.

NCT ID: NCT03696459 Not yet recruiting - Healthy Clinical Trials

A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants

Start date: October 3, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of JNJ-53718678 on QT interval corrected for heart rate (QTc) changes using exposure response analysis in healthy adult participants (Part 2).

NCT ID: NCT03696160 Not yet recruiting - HIV/AIDS Clinical Trials

The Late Presenter Treatment Optimisation Study

Start date: January 2019
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare two different types of HIV treatments, in terms of effectiveness and improvement of side effects, for patients who are diagnosed with a more advanced HIV infection. Patients with advanced HIV infections are otherwise known as 'late presenters'. There are many effective treatments for HIV available; however, for late presenting patients the investigators do not know which type of treatment performs best. This is the first large study to compare treatments for patients in this situation, and the investigators hope that the results of this study will help doctors decide which treatments to use in the future. The two different types of treatment the investigators are comparing both contain a mixture of drugs that work together to combat HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe under the brand name Symtuza®. The Integrase Inhibitor combination (INI). Which is a combination tablet containing: bictegravir, emtricitabine and tenofovir alafenamide. This is a a newer combination which was approved for use in Europe in June 2018 under the brand name of Biktarvy®. The main difference between the two treatments is how each one fights a HIV infection. They both stop a part of the virus from working (i.e. inhibit it), to prevent it from making copies of itself. The PI treatment contains drugs to stop the protease part of the virus, whereas the INI treatment contains drugs to stop the integrase part. In recent studies, it appears that treatments containing integrase inhibitors may be better for late presenting patients. They have been shown to quickly bring down the amount of virus in the body, and the side effects may be more acceptable to late presenters. To compare the two treatments, half of the participants on this study will be given the PI treatment, and the other half will be given the INI treatment.

NCT ID: NCT03696095 Recruiting - Postoperative Pain Clinical Trials

Local Anesthetic Automated Intermittent Administration vs. Continuous Infusion Via Femoral Nerve Block.

Start date: April 16, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the impact of local anesthetic administration regiment through peri-neural femoral nerve catheter on pain and motor block frequency, after total knee arthroplasty.

NCT ID: NCT03693573 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Start date: January 11, 2019
Phase: Phase 3
Study type: Interventional

Study MO39939 is an open-label, single-arm, multicenter trial in patients with unresectable, locally-advanced or metastatic, clear or non-clear cell renal cell carcinoma (RCC) who have not received prior systemic therapy (who are treatment naïve in either the [neo]adjuvant or advanced/metastatic setting for clear and non-clear cell RCC). The study consists of a Screening Period, a Treatment Period, an End of Treatment Visit occurring approximately 30 days after the last dose of study medication, and a Follow-Up Period of 4 years after last patient enrolled.

NCT ID: NCT03693391 Not yet recruiting - Healthy Clinical Trials

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the blocking of [18F]JNJ-64511070 binding in the brain at the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination (tmax) of JNJ-64140284 and determine the exposure/receptor interaction of JNJ-64140284 in healthy male participants following single oral dose administration of JNJ-64140284.

NCT ID: NCT03691337 Recruiting - THA Clinical Trials

Fascia Iliaca Blocks for Total Hip Arthroplasty

Start date: May 15, 2018
Phase: Phase 4
Study type: Interventional

The development of minimal-incision techniques for total hip arthroplasty (THA) with preservation of soft tissue is generally associated with reduction of postoperative pain and increased patient comfort. Although this technique requires a smaller incision than other approaches used for hip surgery, adequate postoperative pain management remains crucial for enhanced recovery and early rehabilitation. The fascia iliaca block (FIB) is commonly used to enhance analgesia after hip replacement surgery, however the effect of FIB volume on analgesia quality and sensory-motor blockade have not been adequately studied. In this study, total postsurgical opioid consumption (morphine equivalents IV in hospital and oral at home) through the first postoperative week will be compared and extent and duration of sensory motor block through the 2-day inpatient stay will be evaluated.